New randomised, double-blind, placebo-controlled phase II clinical study to commence in Q1 CY2021
Evaluates the efficacy and safety of eftilagimod alpha in combination with paclitaxel chemotherapy, compared to placebo plus paclitaxel (as per AIPAC study)
Fully funded by EOC Pharma, trial will involve approx. 152 patients across 20 clinical trial sites in China
Follows encouraging data from Immutep’s ongoing AIPAC Phase IIb study announced end of March and today and presented at the San Antonio Breast Cancer Symposium
Global webinar: 11 December at 8.30 am Australian Easter Daylight Time, details below
Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China.
Mindfulness helps young women after breast cancer, study says
By (0)
Mindfulness, meditation and survivorship education can help young breast cancer survivors overcome depression and other problems, a new study indicates.
About 20% of breast cancer cases occur in women younger than 50, many of whom face significant struggles.
Advertisement For women in their 30s and 40s, the experience with breast cancer and its treatments is substantially different from that of older women, said study author Dr. Patricia Ganz said in a university news release. These women often require more aggressive therapy that can be both disruptive and disfiguring, which can cause high levels of distress, putting them at an increased risk for the negative effects of cancer diagnosis and treatment. Yet, little research has been done on strategies to reduce the depression and manage the stress of this younger population, said Ganz, associate director for population science research at UCLA s Jonsson